Clinical Trial

Clinical Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patients With Refractory Cirrhotic Ascites

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 9, 2025 (before its estimated August 15, 2025 completion). Its status may not reflect the trial's current state.
Summary
The aim of this clinical trial is to evaluate the safety and efficacy of low dose dapagliflozin use along with standard care versus the standard care alone in improving the clinical outcomes of patients with cirrhotic refractory ascites. The main question it aims to answer is the difference in ascites control between the two groups at the end of treatment defined as: Complete response: Disappearance of ascites. Partial response: Presence of ascites not requiring LVP. No response: Presence of ascites requiring LVP. Researchers will compare intervention group receiving dapagliflozin 5m once daily for 3 months along with standard care versus standard care group to evaluate the effectiveness and safety of dapagliflozin in refractory ascites patients.
Trial Details
NCT Number NCT06919523
Lead Sponsor Mansoura University
Conditions Refractory Ascites
Enrollment 70 participants
Start Date 2025-04-15
Primary Completion 2025-08-15 (estimated)
Study Completion 2025-09-15 (estimated)
Updated on ClinicalTrials.gov 2025-04-09